Low Sodium Oxybate

Leiden University Medical Center · FDA-approved active Small molecule

Low Sodium Oxybate is a GHB receptor agonist / GABA-B receptor agonist Small molecule drug developed by Leiden University Medical Center. It is currently FDA-approved for Narcolepsy type 1 with cataplexy, Excessive daytime sleepiness in narcolepsy. Also known as: XYWAV, JZP-258, Xywav, Calcium, Magnesium, Potassium, and Sodium Oxybates.

Low sodium oxybate is a reduced-sodium formulation of sodium oxybate that enhances GABAergic and GHB receptor signaling in the central nervous system to reduce excessive daytime sleepiness and cataplexy.

Low sodium oxybate is a reduced-sodium formulation of sodium oxybate that enhances GABAergic and GHB receptor signaling in the central nervous system to reduce excessive daytime sleepiness and cataplexy. Used for Narcolepsy type 1 with cataplexy, Excessive daytime sleepiness in narcolepsy.

At a glance

Generic name	Low Sodium Oxybate
Also known as	XYWAV, JZP-258, Xywav, Calcium, Magnesium, Potassium, and Sodium Oxybates
Sponsor	Leiden University Medical Center
Drug class	GHB receptor agonist / GABA-B receptor agonist
Target	GHB receptor, GABA-B receptor
Modality	Small molecule
Therapeutic area	Neurology
Phase	FDA-approved

Mechanism of action

Oxybate is a prodrug of gamma-hydroxybutyrate (GHB), which acts as a neuromodulator at GHB receptors and GABA-B receptors in the brain. By lowering sodium content while maintaining therapeutic oxybate levels, this formulation reduces sodium intake burden in patients requiring chronic oxybate therapy, particularly important for those with comorbid hypertension or cardiovascular concerns. The mechanism of action remains identical to standard sodium oxybate, but with improved tolerability regarding sodium-related adverse effects.

Approved indications

• Narcolepsy type 1 with cataplexy
• Excessive daytime sleepiness in narcolepsy

Common side effects

• Nausea
• Dizziness
• Headache
• Enuresis
• Tremor
• Anxiety

Key clinical trials

• Stimulating Amyloid Clearance in Cerebral Amyloid Angiopathy (PHASE2)
• Efficacy, Safety and Tolerability of Low Sodium Oxybate for Nocturnal Cluster Headache Attacks (PHASE2)
• Effect of Low Sodium Oxybate (LXB) on Autonomic Symptom Burden in Idiopathic Hypersomnia Patients With Postural Tachycardia Syndrome (PHASE4)
• A Study to Investigate the Effect of XYWAV on Sleepiness, Polysomnography, and Functional Outcomes in Participants With Idiopathic Hypersomnia or Narcolepsy (PHASE4)
• Low Sodium Oxybate in Patients With Idiopathic Hypersomnia (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Low Sodium Oxybate CI brief — competitive landscape report
• Low Sodium Oxybate updates RSS · CI watch RSS
• Leiden University Medical Center portfolio CI

Frequently asked questions about Low Sodium Oxybate

What is Low Sodium Oxybate?

Low Sodium Oxybate is a GHB receptor agonist / GABA-B receptor agonist drug developed by Leiden University Medical Center, indicated for Narcolepsy type 1 with cataplexy, Excessive daytime sleepiness in narcolepsy.

How does Low Sodium Oxybate work?

Low sodium oxybate is a reduced-sodium formulation of sodium oxybate that enhances GABAergic and GHB receptor signaling in the central nervous system to reduce excessive daytime sleepiness and cataplexy.

What is Low Sodium Oxybate used for?

Low Sodium Oxybate is indicated for Narcolepsy type 1 with cataplexy, Excessive daytime sleepiness in narcolepsy.

Who makes Low Sodium Oxybate?

Low Sodium Oxybate is developed and marketed by Leiden University Medical Center (see full Leiden University Medical Center pipeline at /company/leiden-university-medical-center).

Is Low Sodium Oxybate also known as anything else?

Low Sodium Oxybate is also known as XYWAV, JZP-258, Xywav, Calcium, Magnesium, Potassium, and Sodium Oxybates.

What drug class is Low Sodium Oxybate in?

Low Sodium Oxybate belongs to the GHB receptor agonist / GABA-B receptor agonist class. See all GHB receptor agonist / GABA-B receptor agonist drugs at /class/ghb-receptor-agonist-gaba-b-receptor-agonist.

What development phase is Low Sodium Oxybate in?

Low Sodium Oxybate is FDA-approved (marketed).

What are the side effects of Low Sodium Oxybate?

Common side effects of Low Sodium Oxybate include Nausea, Dizziness, Headache, Enuresis, Tremor, Anxiety.

What does Low Sodium Oxybate target?

Low Sodium Oxybate targets GHB receptor, GABA-B receptor and is a GHB receptor agonist / GABA-B receptor agonist.

Related

• Drug class: All GHB receptor agonist / GABA-B receptor agonist drugs
• Target: All drugs targeting GHB receptor, GABA-B receptor
• Manufacturer: Leiden University Medical Center — full pipeline
• Therapeutic area: All drugs in Neurology
• Indication: Drugs for Narcolepsy type 1 with cataplexy
• Indication: Drugs for Excessive daytime sleepiness in narcolepsy
• Also known as: XYWAV, JZP-258, Xywav, Calcium, Magnesium, Potassium, and Sodium Oxybates